[Federal Register Volume 67, Number 116 (Monday, June 17, 2002)]
[Notices]
[Pages 41252-41253]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-15147]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Activity Dependent 
Neurotrophic Factor (ADNF) III

AGENCY: National Institutes of Health, Public Health Services, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive license to practice the inventions embodied in U.S. 
provisional patent application 60/037,404 filed February 7, 1997 and 
entitled ``Activity Dependent Neurotrophic Factor (ANDF) III,'' PCT 
application PCT/US98/02485 filed on February 6, 1998 and entitled 
``Activity Dependent Neurotrophic Factor (ANDF) III,'' U.S. 
Continuation-in-Part application 09/187,330 filed on November 6, 1999 
and entitled ``Activity Dependent Neurotrophic Factor III (ANDF III),'' 
PCT application PCT/US99/26213 filed February 4, 1999 and entitled 
``Activity Dependent Neurotrophic Factor (ANDF) III,'' U.S. provisional 
patent application 60/208,944 filed on May 31, 2000 and entitled ``Use 
of Activity-Dependent Neurotrophic Factor-Derived Polypeptides for 
Enhancing Learning and Memory,'' U.S. provisional patent application 
60/267,805 filed on February 8, 2001 and entitled ``Prenatal Treatment 
with ADNF Polypeptides to Improve Learning and Memory,'' PCT 
application PCT/US01/17758 filed on May 31, 2001 and entitled ``Use of 
Activity Dependent Neurotrophic Factor Derived Polypeptide for 
Enhancing Learning and Memory: Pre- and Post-Natal Administration.'' 
U.S. patent application 09/267,511 filed on March 12, 1999, PCT 
application PCT/US00/06364 filed on March 10, 2000 and entitled 
``Prevention of Fetal Alcohol Syndrome and Neuronal Cell Death with 
ADNF Polypeptides,'' U.S. provisional patent application 60/149,956 
filed on August 18, 1999, and PCT application PCT/US00/22861 filed on 
August 17, 2000, and entitled ``Orally Active Peptides that Prevent 
Cell Damage and Death,'' to Allon Therapeutics, of San Diego 
California. The patent rights in these inventions have been assigned to 
the United States of America.
    The prospective exclusive license territory will be worldwide. The 
field of use will be all neurodegenerative diseases, but may be limited 
to Alzheimer's disease and stroke.

DATES: Only written comments and/or license applications which are 
received by the National Institutes of Health on or before August 16, 
2002, will be considered.

ADDRESSES: Requests for copies of the patent(s)/patent application(s), 
inquiries, comments and other materials relating to the contemplated 
exclusive license should be directed to: Jonathan V. Dixon, Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; Telephone: 301.496.7056, x270; Facsimile 301.402.0220; 
email [email protected].

SUPPLEMENTARY INFORMATION: The above-referenced patent(s)/patent 
application(s) relate to Activity

[[Page 41253]]

Dependent Neurotrophic factor III (ADNF III) and a specific eight amino 
acid peptide denoted as NAP (NAPVSIQ) derived from the cloned ADNF III. 
NAP has been discovered to have potent neuroprotective properties in 
vitro and in vivo. NAP has been shown to significantly reduce the 
number of apoptotic cells and to protect neurons against numerous 
toxins and cellular stresses including in vitro exictotoxicity, 
oxidative stress, and glucose deprivation. NAP also exhibits 
neuroprotective activity in a variety of animal models including a 
learning deficient apolipoprotein E knockout mice (a model related to 
Alzheimer's disease), mouse paradigms of traumatic head injury 
(associated with an inflammatory response) and fetal alcohol syndrome 
(oxidative stress), and a rat model of cholinotoxicity.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, the NIH receives 
written evidence and argument that establish that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: May 28, 2002.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 02-15147 Filed 6-14-02; 8:45 am]
BILLING CODE 4140-01-P